Is ATYR or CVKD more profitable?

aTyr Pharma's return on equity of -100.14% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets aTyr Pharma N/A -100.14% -73.55% Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media refer more to MGX or CVKD?

In the previous week, Cadrenal Therapeutics had 11 more articles in the media than Metagenomi. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.05 indicating that Metagenomi is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CVKD or MREO more profitable?

Mereo BioPharma Group's return on equity of -81.28% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -411.03% -275.61% Mereo BioPharma Group N/A -81.28% -70.45%

Which has stronger valuation and earnings, CING or CVKD?

Cingulate is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cingulate N/A N/A -$22.45M -$4.23 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is CING or CVKD more profitable?

Cingulate's return on equity of -365.15% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cingulate N/A -365.15% -158.55% Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media favor CING or CVKD?

In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Cingulate. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 9 mentions for Cingulate. Cadrenal Therapeutics' average media sentiment score of -0.05 beat Cingulate's score of -0.10 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cingulate 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ESLA or CVKD?

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Estrella Immunopharma N/A N/A -$13.06M -$0.34 N/A Cadrenal Therapeutics N/A N/A -$13.24M -$5.63 N/A

Is ESLA or CVKD more profitable?

Estrella Immunopharma's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Estrella Immunopharma N/A N/A -397.36% Cadrenal Therapeutics N/A -411.03% -275.61%

Does the media favor ESLA or CVKD?

In the previous week, Cadrenal Therapeutics had 11 more articles in the media than Estrella Immunopharma. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 1 mentions for Estrella Immunopharma. Cadrenal Therapeutics' average media sentiment score of -0.05 beat Estrella Immunopharma's score of -0.25 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Estrella Immunopharma 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cadrenal Therapeutics (CVKD) Competitors

$4.44 +0.13 (+3.02%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$4.51 +0.07 (+1.58%)

As of 06/5/2026 05:16 PM Eastern

Compare

CVKD vs. ATYR, MGX, MREO, CING, and ESLA

Should you buy Cadrenal Therapeutics stock or one of its competitors? MarketBeat compares Cadrenal Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cadrenal Therapeutics include aTyr Pharma (ATYR), Metagenomi (MGX), Mereo BioPharma Group (MREO), Cingulate (CING), and Estrella Immunopharma (ESLA). These companies are all part of the "pharmaceutical products" industry.

How does Cadrenal Therapeutics compare to aTyr Pharma?

aTyr Pharma (NASDAQ:ATYR) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Cadrenal Therapeutics had 12 more articles in the media than aTyr Pharma. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 0 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.05 indicating that aTyr Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
aTyr Pharma	Neutral
Cadrenal Therapeutics	Neutral

Cadrenal Therapeutics has lower revenue, but higher earnings than aTyr Pharma. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
aTyr Pharma	$190K	242.54	-$74.12M	-$0.73	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

aTyr Pharma has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market.

61.7% of aTyr Pharma shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 5.8% of aTyr Pharma shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

aTyr Pharma's return on equity of -100.14% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
aTyr Pharma	N/A	-100.14%	-73.55%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

aTyr Pharma presently has a consensus price target of $21.00, suggesting a potential upside of 4,368.09%. Cadrenal Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 192.79%. Given aTyr Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe aTyr Pharma is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

aTyr Pharma beats Cadrenal Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Metagenomi currently has a consensus target price of $9.00, suggesting a potential upside of 603.13%. Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 192.79%. Given Metagenomi's stronger consensus rating and higher possible upside, research analysts clearly believe Metagenomi is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cadrenal Therapeutics has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Cadrenal Therapeutics has lower revenue, but higher earnings than Metagenomi. Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.91	-$87.87M	-$2.30	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Metagenomi has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 11 more articles in the media than Metagenomi. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.05 indicating that Metagenomi is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Metagenomi beats Cadrenal Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Mereo BioPharma Group?

Cadrenal Therapeutics (NASDAQ:CVKD) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

In the previous week, Cadrenal Therapeutics had 12 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 0 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.00 beat Cadrenal Therapeutics' score of -0.05 indicating that Mereo BioPharma Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Cadrenal Therapeutics	Neutral
Mereo BioPharma Group	Neutral

Cadrenal Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.33, suggesting that its share price is 67% less volatile than the broader market.

Cadrenal Therapeutics presently has a consensus price target of $13.00, indicating a potential upside of 192.79%. Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 937.68%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Mereo BioPharma Group	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are held by institutional investors. 26.1% of Cadrenal Therapeutics shares are held by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cadrenal Therapeutics has higher earnings, but lower revenue than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A
Mereo BioPharma Group	$500K	99.99	-$41.88M	-$0.05	N/A

Mereo BioPharma Group's return on equity of -81.28% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-411.03%	-275.61%
Mereo BioPharma Group	N/A	-81.28%	-70.45%

Summary

Mereo BioPharma Group beats Cadrenal Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Cingulate?

Cingulate (NASDAQ:CING) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Cingulate is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45M	-$4.23	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

41.3% of Cingulate shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 4.3% of Cingulate shares are held by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cingulate's return on equity of -365.15% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-365.15%	-158.55%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Cingulate. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 9 mentions for Cingulate. Cadrenal Therapeutics' average media sentiment score of -0.05 beat Cingulate's score of -0.10 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cingulate has a beta of -0.85, indicating that its stock price is 185% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

Cingulate presently has a consensus target price of $28.33, suggesting a potential upside of 531.03%. Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 192.79%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Cingulate beats Cadrenal Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Estrella Immunopharma?

Estrella Immunopharma (NASDAQ:ESLA) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 5.8% of Estrella Immunopharma shares are held by company insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Estrella Immunopharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Estrella Immunopharma	N/A	N/A	-$13.06M	-$0.34	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$5.63	N/A

Estrella Immunopharma currently has a consensus price target of $8.00, suggesting a potential upside of 601.75%. Cadrenal Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 192.79%. Given Estrella Immunopharma's higher probable upside, equities analysts plainly believe Estrella Immunopharma is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Estrella Immunopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Estrella Immunopharma's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Estrella Immunopharma	N/A	N/A	-397.36%
Cadrenal Therapeutics	N/A	-411.03%	-275.61%

Estrella Immunopharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 11 more articles in the media than Estrella Immunopharma. MarketBeat recorded 12 mentions for Cadrenal Therapeutics and 1 mentions for Estrella Immunopharma. Cadrenal Therapeutics' average media sentiment score of -0.05 beat Estrella Immunopharma's score of -0.25 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Estrella Immunopharma	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cadrenal Therapeutics beats Estrella Immunopharma on 6 of the 10 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.73M	$3.35B	$6.64B	$12.42B
Dividend Yield	N/A	2.33%	2.68%	5.34%
P/E Ratio	N/A	19.02	23.84	23.63
Price / Sales	N/A	308.79	577.54	137.68
Price / Cash	N/A	116.12	42.42	57.17
Price / Book	3.79	6.51	9.73	6.35
Net Income	-$13.24M	$24.19M	$3.57B	$337.59M
7 Day Performance	-10.48%	-6.96%	-1.26%	-2.51%
1 Month Performance	-28.04%	-4.27%	0.82%	-0.69%
1 Year Performance	-70.60%	36.81%	24.09%	25.37%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.6049 of 5 stars	$4.44 +3.0%	$13.00 +192.8%	-69.6%	$12.73M	N/A	N/A	4
ATYR aTyr Pharma	2.4217 of 5 stars	$0.52 -4.9%	$25.67 +4,835.9%	-91.2%	$53.60M	$190K	N/A	53
MGX Metagenomi	1.8107 of 5 stars	$1.33 +1.5%	$9.00 +576.7%	-22.9%	$49.32M	$25.21M	N/A	236
MREO Mereo BioPharma Group	3.0919 of 5 stars	$0.34 +10.3%	$3.25 +857.6%	-87.3%	$49.13M	$500K	N/A	40
CING Cingulate	2.7985 of 5 stars	$4.03 +11.9%	$28.33 +603.1%	+5.9%	$48.49M	N/A	N/A	20	News Coverage Options Volume High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. ATYR, MGX, MREO, CING, and ESLA

How does Cadrenal Therapeutics compare to aTyr Pharma?

Summary

How does Cadrenal Therapeutics compare to Metagenomi?

Summary

How does Cadrenal Therapeutics compare to Mereo BioPharma Group?

Summary

How does Cadrenal Therapeutics compare to Cingulate?

Summary

How does Cadrenal Therapeutics compare to Estrella Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. ATYR, MGX, MREO, CING, and ESLA

How does Cadrenal Therapeutics compare to aTyr Pharma?

Does the media favor ATYR or CVKD?

Which has stronger earnings and valuation, ATYR or CVKD?

Which has more volatility and risk, ATYR or CVKD?

Do institutionals & insiders hold more shares of ATYR or CVKD?

Is ATYR or CVKD more profitable?

Do analysts recommend ATYR or CVKD?

Summary

How does Cadrenal Therapeutics compare to Metagenomi?

Do insiders & institutionals hold more shares of MGX or CVKD?

Do analysts recommend MGX or CVKD?

Is MGX or CVKD more profitable?

Which has better valuation and earnings, MGX or CVKD?

Which has more risk & volatility, MGX or CVKD?

Does the media refer more to MGX or CVKD?

Summary

How does Cadrenal Therapeutics compare to Mereo BioPharma Group?

Does the media refer more to CVKD or MREO?

Which has more risk and volatility, CVKD or MREO?

Do analysts recommend CVKD or MREO?

Do institutionals & insiders believe in CVKD or MREO?

Which has preferable valuation and earnings, CVKD or MREO?

Is CVKD or MREO more profitable?

Summary

How does Cadrenal Therapeutics compare to Cingulate?

Which has stronger valuation and earnings, CING or CVKD?

Do institutionals & insiders have more ownership in CING or CVKD?

Is CING or CVKD more profitable?

Does the media favor CING or CVKD?

Which has more risk and volatility, CING or CVKD?

Do analysts recommend CING or CVKD?

Summary

How does Cadrenal Therapeutics compare to Estrella Immunopharma?

Do insiders & institutionals have more ownership in ESLA or CVKD?

Which has better earnings & valuation, ESLA or CVKD?

Do analysts prefer ESLA or CVKD?

Is ESLA or CVKD more profitable?

Which has more volatility and risk, ESLA or CVKD?

Does the media favor ESLA or CVKD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools